13 Chronic Lymphocytic Leukemia Clinical Trials in Boston, MA (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Chronic Lymphocytic Leukemia Studies in Boston

NCT04028531Recruiting

Understanding Chronic Lymphocytic Leukemia

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemi...

Boston, MA2,750 participantsDana-Farber Cancer Institute

View Study Details

NCT07509151Recruiting

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ ...

Boston, MAPHASE3420 participantsAstraZeneca

View Study Details

NCT06104566Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who pr...

Boston, MAPHASE3400 participantsAscentage Pharma Group Inc.

View Study Details

NCT06876662Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

Boston, MAPHASE4279 participantsEli Lilly and Company

View Study Details

NCT06697184Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies....

Boston, MAPHASE1258 participantsBeiGene

View Study Details

NCT04215809Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax....

Boston, MAPHASE1144 participantsAscentage Pharma Group Inc.

View Study Details

NCT06849713Recruiting

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small...

Boston, MAPHASE280 participantsMassachusetts General Hospital

View Study Details

NCT07024706Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi +...

Boston, MAPHASE280 participantsAstraZeneca

View Study Details

NCT04895436Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

Boston, MAPHASE275 participantsAbbVie

View Study Details

NCT06333262Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphoc...

Boston, MAPHASE260 participantsInhye Ahn

View Study Details

NCT05168930Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lympho...

Boston, MAPHASE245 participantsDana-Farber Cancer Institute

View Study Details

NCT07052695Recruiting

Mosunetuzumab for CLL MRD Clearance

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in partic...

Boston, MAPHASE140 participantsInhye Ahn

View Study Details

NCT07061951Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (...

Boston, MAPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

About Chronic Lymphocytic Leukemia Clinical Trials in Boston

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the blood and bone marrow that affects B lymphocytes. It is the most common type of adult leukemia. Treatment options include targeted therapies, chemotherapy, and immunotherapy.

There are currently 13 chronic lymphocytic leukemia clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 4,651 participants. Research is being sponsored by Dana-Farber Cancer Institute, AstraZeneca, Ascentage Pharma Group Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Chronic Lymphocytic Leukemia Clinical Trials in Boston — FAQ

Are there chronic lymphocytic leukemia clinical trials in Boston?

Yes, there are 13 chronic lymphocytic leukemia clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What chronic lymphocytic leukemia treatments are being tested?

The 13 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for chronic lymphocytic leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov